0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%

Indivior PLC

Healthcare GB INDV

1352.0GBP
-33.0(2.38%)

Last update at 2024-05-16T15:36:00Z

Day Range

1322.001401.00
LowHigh

52 Week Range

1125.002020.00
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -95.00000M 190.00M -173.00000M 180.00M 278.00M
Minority interest - - - - -
Net income -53.00000M 205.00M -148.00000M 134.00M 275.00M
Selling general administrative 545.00M 226.00M 447.00M 196.00M 271.00M
Selling and marketing expenses 218.00M 192.00M 202.00M 199.00M 205.00M
Gross profit 742.00M 664.00M 550.00M 645.00M 877.00M
Reconciled depreciation 21.00M 22.00M 26.00M 28.00M 40.00M
Ebit -91.00000M 213.00M -156.00000M 178.00M 306.00M
Ebitda -51.00000M 207.00M -121.00000M 230.00M 346.00M
Depreciation and amortization 40.00M -6.00000M 35.00M 52.00M 40.00M
Non operating income net other - - - - -
Operating income -91.00000M 213.00M -156.00000M 178.00M 316.00M
Other operating expenses 992.00M 610.00M 803.00M 607.00M 689.00M
Interest expense 29.00M 27.00M 26.00M 22.00M 28.00M
Tax provision -42.00000M -15.00000M -25.00000M 46.00M 3.00M
Interest income 19.00M 4.00M 9.00M 24.00M 17.00M
Net interest income -10.00000M -23.00000M -17.00000M 2.00M -14.00000M
Extraordinary items - - - - 2.00M
Non recurring - - - - -
Other items - - - - -
Income tax expense -42.00000M -15.00000M -25.00000M 46.00M 3.00M
Total revenue 901.00M 791.00M 647.00M 785.00M 1005.00M
Total operating expenses 833.00M 483.00M 706.00M 467.00M 561.00M
Cost of revenue 159.00M 127.00M 97.00M 140.00M 128.00M
Total other income expense net -4.00000M -23.00000M -17.00000M 2.00M -38.00000M
Discontinued operations - - - - -
Net income from continuing ops -53.00000M 205.00M -148.00000M 134.00M 275.00M
Net income applicable to common shares -53.00000M 205.00M -148.00000M 134.00M 275.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1769.00M 1832.00M 1531.00M 1652.00M 1547.00M
Intangible assets 70.00M 82.00M 62.00M 72.00M 84.00M
Earning assets - - - - -
Other current assets 13.00M 14.00M 33.00M 227.00M 327.00M
Total liab 1718.00M 1629.00M 1449.00M 1443.00M 1481.00M
Total stockholder equity 51.00M 203.00M 82.00M 209.00M 66.00M
Deferred long term liab - - - - -
Other current liab 972.00M 61.00M 48.00M 71.00M 218.00M
Common stock 68.00M 70.00M 73.00M 73.00M 73.00M
Capital stock 68.00M 70.00M 73.00M 73.00M 73.00M
Retained earnings 1303.00M 1438.00M 1311.00M 1449.00M 1315.00M
Other liab 433.00M 550.00M 577.00M 417.00M 426.00M
Good will - - - - -
Other assets 257.00M 211.00M 179.00M 113.00M 77.00M
Cash 774.00M 1102.00M 858.00M 1060.00M 924.00M
Cash and equivalents - - - - -
Total current liabilities 1019.00M 804.00M 599.00M 742.00M 818.00M
Current deferred revenue - 595.00M 519.00M 623.00M -
Net debt -497.00000M -816.00000M -573.00000M -767.00000M -683.00000M
Short term debt 11.00M 11.00M 12.00M 9.00M 4.00M
Short long term debt 3.00M 3.00M 4.00M 4.00M 4.00M
Short long term debt total 277.00M 286.00M 285.00M 293.00M 241.00M
Other stockholder equity -1320.00000M -1305.00000M -1302.00000M -1313.00000M -1270.00000M
Property plant equipment 85.00M 95.00M 103.00M 107.00M 57.00M
Total current assets 1259.00M 1444.00M 1187.00M 1360.00M 1329.00M
Long term investments - - - - -
Net tangible assets -19.00000M 121.00M 20.00M 137.00M -18.00000M
Short term investments 119.00M - - - -
Net receivables 239.00M 233.00M 203.00M 192.00M 318.00M
Long term debt 237.00M 239.00M 230.00M 233.00M 237.00M
Inventory 114.00M 95.00M 93.00M 73.00M 78.00M
Accounts payable 36.00M 137.00M 20.00M 39.00M 557.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -60.00000M -52.00000M
Additional paid in capital - - - - -
Common stock total equity - - 73.00M 73.00M 73.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 157.00M 84.00M 82.00M 50.00M 33.00M
Deferred long term asset charges - - - - -
Non current assets total 510.00M 388.00M 344.00M 292.00M 218.00M
Capital lease obligations 37.00M 44.00M 51.00M 56.00M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -223.00000M -14.00000M -4.00000M -2.00000M -4.00000M
Change to liabilities -98.00000M 201.00M -103.00000M -101.00000M 58.00M
Total cashflows from investing activities -223.00000M -14.00000M -4.00000M -2.00000M -4.00000M
Net borrowings -12.00000M 6.00M -11.00000M -13.00000M -240.00000M
Total cash from financing activities -100.00000M -94.00000M -10.00000M -13.00000M -237.00000M
Change to operating activities 269.00M 269.00M 85.00M -64.00000M 35.00M
Net income -85.00000M 213.00M -156.00000M 178.00M 275.00M
Change in cash -328.00000M 244.00M -202.00000M 136.00M 61.00M
Begin period cash flow 1102.00M 858.00M 1060.00M 924.00M 863.00M
End period cash flow 774.00M 1102.00M 858.00M 1060.00M 924.00M
Total cash from operating activities -4.00000M 353.00M -193.00000M 151.00M 303.00M
Issuance of capital stock 2.00M 1.00M 1.00M 0.00000M 3.00M
Depreciation 21.00M 22.00M 26.00M 28.00M 40.00M
Other cashflows from investing activities - - - 1.00M 1.00M
Dividends paid - - - - -
Change to inventory -25.00000M -3.00000M -16.00000M 7.00M -31.00000M
Change to account receivables -21.00000M -25.00000M 15.00M 79.00M -33.00000M
Sale purchase of stock -90.00000M -101.00000M 1.00M - 3.00M
Other cashflows from financing activities -9.00000M 242.00M -7.00000M -9.00000M -4.00000M
Change to netincome -97.00000M -47.00000M -52.00000M 68.00M -41.00000M
Capital expenditures 6.00M 34.00M 4.00M 7.00M 41.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 125.00M 173.00M -19.00000M -79.00000M 29.00M
Stock based compensation 16.00M 11.00M 8.00M 3.00M 15.00M
Other non cash items -81.00000M -66.00000M -52.00000M 21.00M -56.00000M
Free cash flow -10.00000M 319.00M -197.00000M 144.00M 262.00M

Fundamentals

  • Previous Close 1385.00
  • Market Cap1604.53M
  • Volume529939
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA255.00M
  • Revenue TTM1042.00M
  • Revenue Per Share TTM7.61
  • Gross Profit TTM 742.00M
  • Diluted EPS TTM-1.33

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INDV
Indivior PLC
-33.0 2.38% 1352.00 - - 1.60 48.69 1.17 -4.7616
HLN
Haleon PLC
1.10 0.33% 332.40 24.73 16.86 2.63 1.81 3.17 16.57
HIK
Hikma Pharmaceuticals PLC
-45.0 2.22% 1983.00 33.45 11.14 1.45 2.32 1.76 8.98
HCM
HUTCHMED China Ltd
-3.0 0.88% 337.00 - - 3.22 3.97 2.39 -19.4252
HELD
Hellenic Dynamics PLC
-0.075 3.61% 2.00 - - - 2.57 -9.0325

Reports Covered

Stock Research & News

Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Indivior PLC

10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235

Key Executives

Name Title Year Born
Mr. Mark Crossley CEO & Exec. Director NA
Mr. Ryan Preblick CFO & Exec. Director NA
Dr. Christian Heidbreder Chief Scientific Officer NA
Mr. Jason Thompson VP of Investor Relations NA
Ms. Cynthia Cetani Chief Integrity & Compliance Officer NA
Mr. Jeffrey W. Burris Chief Legal Officer 1972
Mr. Jon Fogle Chief HR Officer NA
Mr. Richard Simkin Chief Commercial & Strategy Officer NA
Mr. Hillel West Chief Manufacturing & Supply Officer NA
Ms. Nina DeLorenzo Chief Global Impact Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions